Tuberous Sclerosis Complex
Conditions
Keywords
Tuberous sclerosis complex, Sirolimus, Rapalimus gel, mTOR inhibitor
Brief summary
The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.
Detailed description
This is a Phase 3, placebo-controlled comparative study of NPC-12Y gel in patients with skin lesions associated with tuberous sclerosis complex. Patients who meet all entry criteria for this study will apply NPC-12Y gel or placebo twice a day for 12 weeks. After the double-blind evaluation period, all patients will apply NPC-12Y gel twice a day for 52 weeks. Approximately 40 eligible patients will be enrolled
Interventions
DRUGNPC-12Y gel
NPC-12Y gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
DRUGNPC-12Y placebo gel
NPC-12Y placebo gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
Sponsors
Nobelpharma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
3 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients 3 years old or greater at the time of informed consent 2. Patients who are diagnosed as definite diagnosis according to diagnostic criteria for tuberous sclerosis complex (International Tuberous Sclerosis Complex Consensus Conference 2012) 3. Patients with three or more reddish papules of angiofibroma ( \>= 2 mm in diameter) on the face at screening tests 4. Patients who are not suitable for therapy with laser or surgery (including liquid nitrogen therapy and phototherapy) for angiofibroma, or who do not want therapy with laser or surgery 5. Patients who are being treated with Rapalimus® gel 0.2% (NPC-12G Gel 0.2%) and who are able to and agree to a withdrawal of at least 4 weeks prior to enrollment in this study. 6. Patients who (or whose guardian) give a written informed consent in understanding and willingness after having received enough explanation regarding the study participation.
Exclusion criteria
1. Patients who (or whose guardian) are hard to apply the investigational drug topically with keeping compliance 2. Patients who are hard to be taken pictures of their lesions adequately in such cases that they may not follow instruction of stillness 3. Patients with clinical findings such as erosion, ulcer and eruption on or around the lesion of angiofibroma, which may affect assessment of safety or efficacy 4. Patients with a history or complication of allergy to the component of the investigational drug (sirolimus) 5. Patients who have any infectious disease, cardiac disease, hepatic disease, pulmonary disease, renal disease, hematological disease, or malignant tumor that is considered inappropriate for participation in this clinical study. 6. Patients who have complications such as diseases unsuitable for the trial participation, for examples, uncontrolled diabetes, dyslipidemia, etc. 7. Patients who have participated in other clinical trial or clinical study, and have taken an investigational or clinical study drug within 6 months before the initial registration 8. Patients who used mTOR inhibitors (oral or injectable) other than everolimus within 4 weeks before the initial registration 9. Female patients who are pregnant, may be pregnant, or are lactating 10. Patients who cannot agree to use appropriate contraception after the date of consent to participate in the clinical study and for the duration of the clinical study (including male patients with a partner of childbearing potential) 11. Patients who have received therapy with laser or surgery (including liquid nitrogen therapy and phototherapy) to the lesion of angiofibroma within 6 months before the initial registration 12. Other patients who are considered by the investigator as unsuitable for participation in the clinical study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvements in angiofibroma | 12 weeks | Improvements comparing with baseline is assessed using photograph by IRC |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvements in angiofibroma, color and size | 12 weeks | Improvements comparing with baseline is assessed using photograph by IRC |
| Index of Facial Angiofibromas (IFA) score | 12 weeks | Changes in Index of Facial Angiofibromas (IFA) score assessed by investigators |
Countries
Japan
Outcome results
None listed